Activates B1 (induced by inflammation) and B2 (constitutive) receptors — vasodilation, increased vascular permeability, pain.
Reference facts
- Also known as
- BK
- Category
- Neuropeptide & Other
- Mechanism of action
- Activates B1 (induced by inflammation) and B2 (constitutive) receptors — vasodilation, increased vascular permeability, pain.
- Targets
- B1R, B2R
- Indications under research or approved
- Research target (Icatibant, a B2 antagonist, treats hereditary angioedema)
- Regulatory status (reference entry)
- Native not approved; antagonists are
- Half-life
- ~17 seconds
- Sequence
- RPPGFSPFR
- Sequence notes
- Nonapeptide cleaved by kallikreins from kininogen.
- Molecular weight (Da)
- 1060
- First reported
- 1949
Primary References
Explore research articles about Bradykinin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.